Trial results

$MAZE — MZE829

Maze Therapeutics, Inc. (MAZE) MZE829: trial results in AMKD, 2027.

Research by Catalyst Intel

The catalyst

"Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027"

— Maze Therapeutics, 8-K filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

MAZE-MZE829-2026

Company

Maze Therapeutics, Inc.

Kind

Trial results

Indication

AMKD

Window

2027-01-01 – 2027-04-30

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.